No abstract

Keywords: Molecular modeling / sPLA 2 / Inflammation / Oxadiazolone 3-(4-Tetradecyloxybenzyl)-4H-1,2,4-oxadiazol-5-one (PMS1062 or I) can probably act as a PLA 2 -II inhibitor on the acute inflammation model, but its highly lipophilic character could prevent it from being biodistributed effectively. In this work, based on a molecular modeling study, we have proposed a model that may provide compounds retaining both anti-PLA 2 activity and specificity while becoming active per os. Moreover, molecular dynamics and energy minimization enabled us to characterize the lowest-energy complexes of each derivative. Energy balances taking account of the conformational energy changes of both partners, along with the drug-

No abstract